{{Rsnum
|rsid=1413711
|Gene=VEGFA
|Chromosome=6
|position=43772941
|Orientation=minus
|GMAF=0.3581
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=VEGFA
}}{{PMID Auto
|PMID=20847577
|Title=Vascular Endothelial Growth Factor Gene Polymorphisms and Risk of Neovascular Age-Related Macular Degeneration in a Chinese Cohort
}}
{{omim
|id=192240
|rsnum=1413711
}}
{{omim
|id=264800
|rsnum=1413711
}}
{{PMID Auto
|PMID=21881842
|Title=Homozygosity for the +674C&gt;T polymorphism on VEGF gene is associated with age-related macular degeneration in a Brazilian cohort
}}{{PMID Auto
|PMID=18378209
|Title=Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration.
}}

{{PMID Auto
|PMID=20019880
|Title=Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration.
|OA=1
}}

{{PMID Auto
|PMID=21242666
|Title=Polymorphisms of hypoxia-related genes in subjects susceptible to acute mountain sickness.
}}

{{PMID Auto
|PMID=21558292
|Title=CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
}}

{{PMID Auto
|PMID=22307787
|Title=Pooled-analysis of the associations between three polymorphisms in the VEGF gene and age-related macular degeneration.
}}

{{PMID Auto
|PMID=22521084
|Title=Role of Vascular Endothelial Growth Factor Polymorphisms in the Treatment Success in Patients with Wet Age-related Macular Degeneration.
}}
{{PMID Auto
|PMID=24080590
|Title=Genetic Association with Response to Intravitreal Ranibizumab for Neovascular Age-Related Macular Degeneration in the Han Chinese Population
}}
{{PMID Auto
|PMID=24157918
|Title=VEGF Gene Polymorphism and Response to Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration
}}
{{PMID Auto
|PMID=24652518
|Title=VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT)
}}